Groep Brussel Lambert NV (GBLB)
Euronext Brussels · Belgium · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 75.80 |
|---|---|
| 52-week range | 67.90 – 85.65 |
| Return, 1 month / 3 months | +3.0% / −2.8% |
| Return, 1 year / 3 years | +3.4% / +31.2% |
| Trend | Below its 200-day average |
| RSI (14) | 71 |
| Volatility (1 year) | 16.0% |
| Worst drawdown (1 year) | -17.8% |
| Average daily value traded | 7.08M EUR |
| Dividend yield | 6.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Groupe Bruxelles Lambert is a Belgian holding company based in Brussels that owns significant stakes in a range of businesses. Its portfolio spans consumer goods, industrial services and other sectors, with holdings in companies active in sportswear, spirits and testing and certification services. The company acts as a long-term investor, supporting the management of the firms in which it holds interests and managing a diversified collection of investments on behalf of its shareholders.
The shares are listed on the Euronext Brussels in Belgium under the code GBLB, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Groep Brussel Lambert NV (GBLB) trades on the Euronext Brussels in Belgium. It last closed at EUR 75.80 on 23 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 26 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 3.4% and over the last three months it fell 2.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -0.3% | ||
| From 52-week high | -11.2% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -2.8% | ||
| 6-month return | 0.5% | ||
| 12-month return, skipping the last month | 0.4% | ||
| Stability (higher is calmer) | 79 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 16.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.8% | ||
| Liquidity | 87 · Strong | Trades actively. | |
| Average daily value traded | 7.08M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 68 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 6.8% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +5.4% |
|---|---|
| 1 month | +3.0% |
| 3 months | −2.8% |
| 6 months | +0.5% |
| 1 year | +3.4% |
| 3 years | +31.2% |
| 5 years | −2.9% |
Signals
| 50-day / 200-day average | 72.81 / 76.05 |
|---|---|
| Golden / death cross (60 days) | Death, 26 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.10 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 May 2026 | EUR 5.1250 |
| 9 May 2025 | EUR 5.0000 |
| 9 May 2024 | EUR 2.7500 |
| 11 May 2023 | EUR 2.7500 |
| 3 May 2022 | EUR 2.7500 |
| 4 May 2021 | EUR 2.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.